Mandate

Vinge advises Agnico Eagle in connection with its acquisition of a majority stake in and joint venture regarding Gunnarn Mining AB

June 18, 2015 M&A

Vinge advises Agnico Eagle Mines Limited in connection with its acquisition of a 55% interest in Gunnarn Mining AB, the owner of the Barsele Gold Project, from Orex Minerals Inc. for US $10 million and the entering into of a joint venture agreement for the management and operation of Gunnarn Mining AB and the exploration and development of the Barsele project. As part of the transaction, Agnico Eagle granted a royalty interest in the project to Orex, has committed to spend US $7 million over three years and will earn an additional 15% interest in Gunnarn Mining AB if it completes a pre-feasibility study. The transaction was completed on 11 June 2015.

Vinge advises Agnico Eagle on Swedish law matters and in co-operation with Davies Ward Phillips & Vineberg LLP. Vinge’s team consists of M&A partners Malin Ohlin and Peter Sundgren, associates Kajsa Hallner (M&A), Isabell Nielsen (commercial agreements), Lova Unge (employment and benefits), Tora Hansjons (tax) and counsels Maria Schultzberg (tax) and Johan Cederblad (real estate and environment).

 

Related

Vinge has advised Egetis Therapeutics in connection with a directed share issue

Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025

Vinge worked with funds advised by Agilitas on the buy-out of Vivicta (previously Tietoevry Tech Services), including on the issuance of senior secured bonds and on entering into a super senior RCF

Vinge, together with O’Melveny as lead counsel and Avance, worked with funds advised by Agilitas Private Equity LLP (“Agilitas”), the pan-European mid-market private equity firm, in their backing of Vivicta. The buy-out was previously announced on 24 March 2025 and closed on 2 September 2025.
October 03, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 671.5 million

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of approx. SEK 671.5 million before transaction costs.
October 03, 2025